Steve Giordano
@Casdin Capital, Llc
Latest period2024 - Q3ReportedManaged Assets$1.5BTotal holdings35
Assets growth rate14.98%Assets growth rate (2-Q avg)5.98%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Casdin Capital, Llc's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 35 positions.
Assets under management
The assets under management (AUM) of Casdin Capital, Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 1.5B in assets, with a quarterly growth rate of 14.98% and a 2-quarter average growth rate of 5.98%. The portfolio is managed by Steve Giordano, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
RVMDRevolution Medicines Inc
| 12.44% | $186.583M 4.114M shares@ $45.35 avg price | Decreased -6.63% |
WGSGenedx Holdings Corp
| 9.93% | $148.844M 3.507M shares@ $42.44 avg price | Decreased -0.54% |
DNLIDenali Therapeutics Inc
| 1.93% | $28.839M 990,000 shares@ $29.13 avg price | Decreased -23.84% |
VCYTVeracyte Inc
| 1.52% | $22.681M 666,308 shares@ $34.04 avg price | Decreased -22.33% |
GLUEMonte Rosa Therapeutics Inc
| 0.04% | $455,874 86,014 shares@ $5.3 avg price | Decreased -67.04% |